Evonile Pharma (500672) Q3 25/26 earnings summary

Executive summary

• Q3 FY26 revenue from operations was 859.0 million; profit for the period was 160.9 million, compared with 930.0 million and 254.5 million in Q3 FY25.

• Nine-month revenue was 2,637.8 million and profit was 679.3 million, versus 2,723.9 million and 716.0 million in 9M FY25.

Financial highlights

• Q3 total income was 946.5 million, versus 1,036.0 million in Q3 FY25; total expenses were 650.0 million, versus 683.1 million.

• Q3 profit before tax was 296.5 million, versus 352.9 million in Q3 FY25; total tax expense was 135.6 million, versus 98.4 million.

• 9M total income was 2,925.4 million and total expenses were 1,930.2 million, versus 3,037.2 million and 2,071.9 million in 9M FY25.

• 9M profit before tax was 995.2 million, versus 965.3 million in 9M FY25; total tax expense was 315.9 million, versus 249.3 million.

Segment performance

• Operations comprise one reportable business segment: Pharmaceuticals Business.